CTEV
Claritev Corporation
CTEV lost money over the past year, so it has no meaningful PE right now.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CTEV Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Under pressure | |
| Weak |
CTEV's revenue and profitability are currently stable, but its cash flow and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CTEV PE Valuation
CTEV has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CTEV Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Growth | |
| Stable | |
| Limited | |
| High |
CTEV has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CTEV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$16.42 | +$4.87 |
| Q2 2026 | -$17.01 | +$24.30 |
| Q1 2026 | -$17.33 | +$55.77 |
| Q4 2025 | -$17.30 | +$84.62 |
| Q3 2025 | -$21.29 | +$73.36 |
| Q2 2025 | -$41.31 | +$30.69 |
| Q1 2025 | -$73.10 | -$34.30 |
| Q4 2024 | -$101.92 | -$96.32 |
CTEV has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CTEV Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $268.3M | +9.1% |
| Q2 2026 | $257.5M | +6.6% |
| Q1 2026 | $244.7M | +5.8% |
| Q4 2025 | $246.6M | +6.2% |
| Q3 2025 | $246M | +6.7% |
| Q2 2025 | $241.6M | +3.5% |
| Q1 2025 | $231.3M | -1.4% |
| Q4 2024 | $232.1M | -4.9% |
CTEV's revenue has grown year over year for six quarters in a row: $268M last quarter, up 9.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 7.7% | +3.6 points |
| Q2 2026 | 9.1% | +2.2 points |
| Q1 2026 | 2.7% | -1.5 points |
| Q4 2025 | -3.1% | +15 points |
| Q3 2025 | 4.1% | +151 points |
| Q2 2025 | 6.9% | +231 points |
| Q1 2025 | 4.2% | +212 points |
| Q4 2024 | -18% | -35 points |
CTEV has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over CTEV on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
CTEV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.2M | -$9.9M |
| Q2 2026 | $54.6M | +49% |
| Q1 2026 | -$92.5M | -$23.6M |
| Q4 2025 | $36.4M | +$100.2M |
| Q3 2025 | -$16.3M | -140% |
| Q2 2025 | $36.6M | +$43.6M |
| Q1 2025 | -$68.9M | -459% |
| Q4 2024 | -$63.8M | -$60.2M |
CTEV's free cash flow was −$28M over the past year, against −$113M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CTEV on cash generation, producing positive trailing cash flow while its opponent burns cash.
CTEV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +10.3K shares |
| 1 year | +3% | +495K shares |
| 3 years | +5% | +814K shares |
| 5 years | +4% | +653K shares |
| Available history | +562% | +14.4M shares |
CTEV has 17M diluted shares, up 3% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CTEV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CTEV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 9.4x | High |
| Q2 2026 | 9.6x | High |
| Q1 2026 | 9.7x | High |
| Q4 2025 | 9.6x | High |
| Q3 2025 | 10.3x | High |
| Q2 2025 | 52.3x | High |
| Q1 2024 | 85.5x | High |
| Q4 2023 | 7.7x | High |
CTEV's net debt is about 9.4 years of its operating earnings (EBITDA), down from 10 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CTEV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.9 | Neutral |
| Stochastic | 21.6 | Neutral |
CTEV's weekly RSI is 49 (neutral) and its Stochastic is 22 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CTEV PE vs Healthcare Sector
| Metric | CTEV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
CTEV has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CTEV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $23.9 | 13% above |
| 20 week MA | $29.1 | 7.6% below |
| 50 week MA | $26.9 | 0.1% below |
| 100 week MA | $32.3 | 17% below |
| 200 week MA | $36.3 | 26% below |
CTEV has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CTEV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $388.8 | $357.2 | -8.1% |
| 2021 | $357.2 | $176.8 | -51% |
| 2022 | $176.8 | $47.6 | -73% |
| 2023 | $47.6 | $57.6 | +21% |
| 2024 | $57.6 | $17.5 | -70% |
| 2025 | $17.5 | $42.0 | +140% |
| 2026 YTD | $42.0 | $26.9 | -36% |
CTEV has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.